A phase II study to evaluate the erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Phase of Trial: Phase IV
Latest Information Update: 18 Nov 2015
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 18 Nov 2015 New trial record